Image (Cimerli 01)
Cimerli Injection, Solution
Product Images NDC 70114-441
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Cimerli (NDC 70114-441). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Coherus Biosciences Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (Cimerli 02)
Image (Cimerli 03)
Image (Cimerli 04)
Image (Cimerli 05)
Figure 1 (Cimerli 06)
This is a tabular data that depicts the mean change in visual acuity for two different periods (one for AMD-1 and one for AMD-2). There is a comparison between the impact of the two different treatments (Ranibizumab 0.5 mg and Verteporfin PDT) and sham treatment. The change in visual acuity is measured based on the number of letters by which the visual acuity changes. The table shows the data for the two periods and the different treatments administered to the patients.*
Figure 2 (Cimerli 07)
Figure 3 (Cimerli 08)
Figure 4 (Cimerli 09)
This document appears to be a chart or graph displaying the percentage of patients who have received a certain number of injections. The mean number of injections for these patients is 10.3. However, the chart itself is not available in this text.*
Figure 5 (Cimerli 10)
Figure 6 (Cimerli 11)
Mean Change in Visual Acuity over a period of months for patients treated with Ranibizumab 0.3 mg (n=125) and Sham (n=127) in a clinical study. The study involved monitoring the changes in visual acuity using a chart for each patient over a period of time. The chart shows the mean changes in visual acuity in both treatment groups over the study period.*
Figure 7 (Cimerli 12)
Figure 8 (Cimerli 13)
This is a data table showing percentages of eyes (upper 95% Cl) with either 3-step or 2-step improvement in Year 1 and Year 2. The data is further divided into two categories: eyes with baseline diabetic macular edema (DME) and eyes without baseline DME. There are three values in each row corresponding to the percentage of eyes with either 3-step or 2-step improvement seen in 75%, 50%, and 25% of the instances. There is no clear context to this table to provide further information.*
Figure 9 (Cimerli 14)
Principal Display Panel (0.3 mg Vial Carton)
This is a medication called CIMERLD, also known as ranibizumab-eqrn, which is injected into the eye for the treatment of diabetic macular edema and diabetic retinopathy. Each box contains one single-dose vial and prescribing information. The vial contains 0.3mg of the medication. This product requires a prescription and should only be used for intravitreal administration. NDC 7011444001 is the National Drug Code for this medication.*
Principal Display Panel (0.5 mg Vial Carton)
CIMERLD is a medication that comes in a single-dose glass vial of 0.5 mg of the injection ranibizumab-eqrn. It is for intravitreal use and its use is restricted to prescription only. It is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. The carton contains only one single-dose vial of the medication. Prescribing information for CIMERLD is available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
